Urine drug screens. Screening Methods

Size: px
Start display at page:

Download "Urine drug screens. Screening Methods"

Transcription

1 Screening Methods Urine drug screens Urine drug screens are generally performed using either immunoassays or gas chromatography-mass spectrometry (GC-MS). 2 Immunoassay UDS contain specific antibodies against common drugs of abuse and their metabolites. The immunoassay is the most commonly used UDS because it is inexpensive and rapid. Five different immunoassays are available: cloned enzyme donor immunoassay, enzyme-multiplied immunoassay (EMIT), fluorescence polarization immunoassay (FPIA), and immunoturbidimetic assay radioimmunoassay (RIA). The substances most commonly tested by a typical immunoassay include amphetamines, cannabinoid metabolites, cocaine metabolites, opiate metabolites, and phencyclidine (PCP). Expanded immunoassays are available to test for tricyclic antidepressants, barbiturates, methadone, alcohol, and benzodiazepines and may be beneficial when use of these substances is suspected. One major problem with immunoassays is a false-positive result. Therefore, a more specific confirmatory test, such as GC-MS, is needed to confirm a positive finding with an immunoassay. GC-MS is more accurate than an immunoassay, but it is more expensive and time consuming. 1 GC-MS breaks down drug molecules into ionized fragments and identifies substances based on mass-to-charge ratio using a mass spectrometer. Although blood, hair, nails, or saliva can be used, most screening is done using urine samples. 2 Ease of collection, higher drug concentrations, and longer durations of detection are primary reasons for using urine samples for drug screening. Table 1 lists common drugs of abuse and their duration of detection in the urine. Table 1. Length of time drugs of abuse can be detected in the urine. 1,2 Drug/drug class Detection time Drug/drug class Detection time Alcohol 7 to 12 hours Marijuana Amphetamine 48 hours Single use 3 days Methamphetamine 48 hours Moderate use (4x/week) 5 to 7 days Barbiturates Daily use 10 to 15 days Short-acting 24 hours Long-term heavy smoker >30 days Long-acting 3 weeks Opiates Benzodiazepine Codeine 48 hours Short-acting 3 days Heroin (morphine) 2 to 4 days Long-acting 30 days Hydromorphone 2 to 4 days Cocaine metabolites 2 to 4 days Methadone 3 days Morphine 48 to 72 hours Oxycodone 2 to 4 days Propoxyphene 6 to 48 hours Phencyclidine 8 days Collection Methods and Criteria Proper urine collection methods must be used to avoid false-negative results. Urine should be collected in a tamper-evident container under supervision if necessary. 1 Criteria for legitimate urine samples include: A volume of 30 ml or more Temperature between 32 C and 38 C ph of 4.5 to 8.5 Nitrates <500 mcg/ml Specific gravity >1.002 and <1.020 Creatinine >20 mg/dl Urine samples with characteristics outside of these ranges, or with a cloudy or dark appearance, may be adulterated in some manner, either diluted or substituted.

2 Urine Drug Test Results The United States Department of Health and Human Services (DHHS) sets the threshold for drug concentrations for detection by UDS. 2 Drug concentrations in the urine below this level are reported as negative. Table 2 contains a list of these values. However, despite standardization, inaccurate results can occur. Table 2. Standard threshold levels for screening and confirmatory tests 1,3 Drug/drug class Immunoassay screen a (ng/ml) GC/MS confirmation a (ng/ml) Amphetamine and methamphetamine Barbiturates Benzodiazepines Cocaine metabolite (benzoylecgonine) Marijuana metabolites (delta tetrahydrocannabinol-9- carboxylic acid) Methadone Opiates (codeine and morphine) 2,000 2,000 Phencyclidine Propoxyphene a Standard cutoff levels; alternate cutoff levels may be available. Abbreviation: GC-MS, Gas chromatography-mass spectrometry. False-Negative Results False negatives are uncommon but can occur as a result of low drug concentrations in the urine, tampering, and in other situations. Possible reasons for false-negative results include: 1,2 Dilute urine (excess fluid intake, diuretic use, pediatric sample) Infrequent drug use Prolonged time since last use Recent ingestion Insufficient quantity ingested Metabolic factors Inappropriate test used Elevated urine lactate Tampering o Tetrahydrozoline (eye drops) o Bleach o Vinegar o Soap o Ammonia o Lemon juice o Drain cleaner o Table salt o Various chemicals (glutaraldehyde, sodium or potassium nitrate, pyridinium chlorochromate, and peroxide/peroxidase)

3 Understanding the UDS and ordering the appropriate test can prevent false-negative results. Results from an immunoassay or a GC-MS can be deceiving, as these tests may not be able to detect every drug in a particular drug class. 2 This particularly pertains to the opiate and amphetamine/methamphetamine immunoassays. For example, a test for opiates will detect morphine and drugs that are metabolized to morphine, such as codeine and heroin. Heroin itself can only be detected for up to 8 hours after use. After 8 hours, only the morphine metabolite of heroin will be detected in the urine by immunoassay or by GC-MS. Other opiates such as fentanyl, oxycodone, methadone, hydrocodone, buprenorphine, and tramadol will not be detected and require an expanded immunoassay panel for detection. 1 The amphetamine/ methamphetamine immunoassay can detect racemic compounds (dextroamphetamine, methamphetamine) and illicit analogues (methylenedioxyethylamphetamine, methylenedioxyamphetamine, and methylenedioxymethylamphetamine [MDMA]). This assay, however, has a low sensitivity for MDMA and a more specific test should be performed if MDMA is suspected. False-Positive Results Although immunoassays are very sensitive to the presence of drugs and drug metabolites, specificity and accuracy varies depending on the assay used and the substance for detection. 2 This limitation may result in false-positives from substances cross-reacting with the immunoassay. Positive results seen on immunoassay need to be confirmed using the more accurate GC-MS, the forensic standard. The DHHS detection limits reduce false-positive results, but do not eliminate them. In 1998, the cut-off for opiates was raised from 300 ng/ml to 2000 ng/ml to avoid false positives from poppy seed ingestion. However, these more stringent requirements can lead to false-negatives and many laboratories continue to use the lower value for detection. For example, detectable levels of cannabinoids after ingestion of hemp-containing foods with immunoassay have been reported. Levels of cannabinoids in these samples, however, were not detectable with GC-MS. Passive marijuana or cocaine smoke inhalation has never been documented to achieve detectable urine concentrations in adults, however, passive cocaine smoke inhalation has achieved detectable levels in pediatric cases. GC-MS is very accurate; however, it is not without problems in drug detection. 2 As mentioned earlier, heroin and hydrocodone are metabolized into morphine and hydromorphone respectively, and GC-MS may identify the metabolites rather than the parent compound. Selegiline is metabolized to l-amphetamine and l- methamphetamine, isomers without central nervous system stimulation. Neither immunoassay nor GC-MS can differentiate between the l and d isomers and a positive result for amphetamines will be found; an alternative test, chiral chromatography, may be needed. Many prescription and nonprescription substances have been reported to cross-react with immunoassays and cause false-positives. 2 Most have only been documented in case reports. Table 3 lists substances reported to cause false-positive results using immunoassay. This list may not include all potential substances. The frequency of false-positives varies, depending on the specificity of immunoassay used and the substance under detection. Immunoassay results for cannabinoid and cocaine metabolites are associated with very few falsepositives while immunoassay results for amphetamines and opiates are associated with a higher number of false-positives. 1

4 Table 3. Substances that may cause false-positives on immunoassay urine drug screens. 1-7 Drug/drug class Interfering drug Drug/drug class Interfering drug Amphetamine and Amantadine Cocaine Amoxicillin methamphetamine Brompheniramine Coca leaf teas Bupropion Tonic water Chlorpromazine Methadone Chlorpromazine Desipramine Clomipramine Desoxyephedrine Ephedrine Doxylamine Fluoxetine Isometheptene Quetiapine Isoxsuprine Thioridazine Labetalol Verapamil Phentermine Opiates Dextromethorphan Phenylephrine Phenylpropanolamine Fluoroquinolones a Poppy seeds and oil Pseudoephedrine Rifampin Ranitidine Quinine Selegiline Phencyclidine Dextroamphetamine Thioridazine Dextromethorphan Trazodone Trimethobenzamide Doxylamine Trimipramine Vicks inhaler b Imipramine Barbiturates Ketamine Naproxen Meperidine Benzodiazepines Oxaprozin Thioridazine Sertraline Tramadol Cannabinoids Dronabinol Venlafaxine Efavirenz Tricyclic Carbamazepine Hemp-containing foods antidepressants Cyclobenzaprine Cyproheptadine Ketoprofen Naproxen Hydroxyzine Piroxicam Quetiapine Lyseric acid Amitriptyline Proton pump inhibitors c diethylamine (LSD) Dicyclomine Sulindac Ergotamine Tolmetin Sumatriptan a Ciprofloxacin, levofloxacin, and ofloxacin. b Vicks inhaler due to l-methamphetamine content interfered with older immunoassays; interference has not been seen with new enzyme multiplied immunoassay tests (EMIT). c Pantoprazole.

5 Summary The strengths and limitations of UDS need to be fully understood in order to perform the correct screen and also to correctly interpret the results. All positive results on immunoassay are presumptive until confirmed using GC-MS. An extensive medication history including prescription, nonprescription, and herbal medications should be obtained from the patient. Medication histories are important in order to anticipate false-positives as well as differentiate between drugs used for legitimate medical purposes and drugs of abuse. References 1. Standridge JB, Adams SM, Zotos AP. Urine drug screen: a valuable office procedure. Am Fam Physician. 2010;81(5): Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1): Quest Diagnostics. Standard urine testing for drug and alcohol abuse. Accessed Nov 11, Vincent EC, Zebelman A, Goodwin C. What common substances can cause false positives on urine drug screens for drugs of abuse? J Fam Pract. 2006;55(10): , Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health-Syst Pharm. 2010;67(16): Holtorf K. Ur-ine Trouble. Scottsdale, AZ: Vandalay Press; Woelfel JA. Drug abuse urine tests: false-positive results. Pharmacist's Letter/Prescriber's Letter. 2005;21(3): Prepared by: Krista Williams, PharmD

Substance Abuse & Diversion in Palliative Care

Substance Abuse & Diversion in Palliative Care Substance Abuse & Diversion in Palliative Care Screening Survey Tools Select the right tool(s) for your purposes and practice Patient self-administers vs Clinician interview Length vs Thoroughness Substances

More information

False Positive and False Negative Results in Urine Drug Screening Tests: Tampering Methods and Specimen Integrity Tests

False Positive and False Negative Results in Urine Drug Screening Tests: Tampering Methods and Specimen Integrity Tests April 30, 2014 Archives 2014 vol.1 102-108 False Positive and False Negative Results in Urine Drug Screening Tests: Tampering Methods and Specimen Integrity Tests Bamdad Riahi-Zanjani Medical Toxicology

More information

Urine Drug Testing. Why drug test? Set the Standard!

Urine Drug Testing. Why drug test? Set the Standard! Urine Drug Testing Urine drug testing is a valuable tool for the physician when making treatment decisions. Patients and physicians benefit from safe and effective treatment of pain but there are always

More information

Appropriate Use of UDT to Improve Patient Care

Appropriate Use of UDT to Improve Patient Care Published on OpioidRisk (http://www.opioidrisk.com) Home > Urine Drug Testing Urine Drug Testing This guide provides: Download Entire Guide [1] Appropriate use of Urine Drug Testing (UDT) to improve patient

More information

Amy LaHood MD MPH FAAFP December 19, 2012

Amy LaHood MD MPH FAAFP December 19, 2012 Amy LaHood MD MPH FAAFP December 19, 2012 Identify trends & consequences of the current opioid epidemic Review evidence & expert guidelines for prescribing controlled substances Identify challenges/solutions

More information

Toxicology CPT Code Changes for 2016

Toxicology CPT Code Changes for 2016 Beginning January 1, 2016, CMS deleted all 2015 drug testing G codes and will continue to not recognize the AMA CPT codes for drug testing. CMS created three G codes for presumptive testing and four G

More information

Central Government Laboratory Department of Health and Environment

Central Government Laboratory Department of Health and Environment Central Government Laboratory Department of Health and Environment Overview who we are and what we do What is available and what is protocol for good science Sample collection Screening Tests Confirmation

More information

Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction

Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction Drug testing beyond the health care and criminal justice systems has

More information

An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse

An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse Drug Testing An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse Printed on August 18, 2016 1:59 pm CST 2016 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved.

More information

Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)

Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP) Appendix D: Urine Drug Testing for Monitoring Opioid Therapy i. Monitoring opioid therapy with urine drug testing (UDT) ii. UDT algorithm for monitoring opioid therapy iii. UDT clinical vignettes iv. Frequently

More information

Drug testing beyond the health care and criminal. Urine Drug Screening: Practical Guide for Clinicians REVIEW

Drug testing beyond the health care and criminal. Urine Drug Screening: Practical Guide for Clinicians REVIEW REVIEW URINE DRUG SCREENING Urine Drug Screening: Practical Guide for Clinicians KAREN E. MOELLER, PHARMD, BCPP; KELLY C. LEE, PHARMD, BCPP; AND JULIE C. KISSACK, PHARMD, BCPP Drug testing, commonly used

More information

DUI in Southern Ohio MATT 2006

DUI in Southern Ohio MATT 2006 DUI in Southern Ohio MATT 2006 Laureen J. Marinetti, M.S., Ph.D. Chief Toxicologist Montgomery County Coroner s s Office & Miami Valley Regional Crime Lab (MVRCL) Dayton, Ohio Region The MVRCL is a regional

More information

Drug Utilization Is On The Rise

Drug Utilization Is On The Rise Objectives Identify the clinical issues related to opioid prescribing for chronic pain indications Define the clinical needs and expectations of urine drug testing in pain management Address preanalytical

More information

This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics

This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion

More information

What Does the Drug Test Tell Us

What Does the Drug Test Tell Us What Does the Drug Test Tell Us QUALITATIVE TOXICOLOGY TESTING for CLINICAL MANAGEMENT of the PATIENT Background The qualitative drug test is often referred to as the drug screen - a misnomer Testing performed

More information

Understanding Drug Screens & PharmCAS Drug Screening Program Overview. Suzi Arant, Senior Business Developer July 8, 2011

Understanding Drug Screens & PharmCAS Drug Screening Program Overview. Suzi Arant, Senior Business Developer July 8, 2011 Understanding Drug Screens & PharmCAS Drug Screening Program Overview Suzi Arant, Senior Business Developer July 8, 2011 Presentation Overview Drug Screening in Healthcare Drug Screening Panels Drugs of

More information

Urine Drug Testing, Advantages and Disadvantages. Advantages

Urine Drug Testing, Advantages and Disadvantages. Advantages overview [chemistry] Urine Drug Testing: Approaches to Screening and Confirmation Testing Gifford Lum, MD, Barry Mushlin, MA VA Boston Healthcare System, Boston, MA DOI: 10.1309/QHJCKA4235EGPEGF 368 Most

More information

Urine Drug Testing Methadone 101 Methadone for hospitalists

Urine Drug Testing Methadone 101 Methadone for hospitalists Urine Drug Testing Methadone 101 Methadone for hospitalists Dr. Patricia Mark MB, BCh LEARNING OBJECTIVES Clarify the purpose of urine drug testing Distinguish between UDT for detection of illicit drug

More information

The potential of oral fluid as a specimen in various drug testing programs

The potential of oral fluid as a specimen in various drug testing programs The potential of oral fluid as a specimen in various drug testing programs *Christine Moore, Cynthia Coulter, Katherine Crompton, Warren Rodrigues, Michael Vincent, James Soares Immunalysis Corporation,

More information

Appropriate utilization of drug tests for pain management patients

Appropriate utilization of drug tests for pain management patients Appropriate utilization of drug tests for pain management patients Gwen McMillin, PhD, DABCC (CC, TC) Medical Director, Toxicology, ARUP Laboratories Associate Professor (clinical), University of Utah

More information

Drug Testing Reference Tables for Drug Courts

Drug Testing Reference Tables for Drug Courts Drug Testing Reference Tables for Drug Courts July, 2009 Page 1 TABLE I. Specimen Detection Period Advantages Disadvantages URINE SWEAT (patch) ORAL FLUID (saliva) Provides a profile of both current and

More information

Drug Testing in the Pain Management Setting

Drug Testing in the Pain Management Setting Drug Testing in the Pain Management Setting September 27, 2011 Gwen McMillin, PhD, DABCC University of Utah, ARUP Laboratories Disclosure Laboratory director consultant for Clinical Lab Consulting, LLC

More information

FREQUENTLY ASKED QUESTIONS Oral Fluid Drug Testing with Oral-Eze

FREQUENTLY ASKED QUESTIONS Oral Fluid Drug Testing with Oral-Eze FREQUENTLY ASKED QUESTIONS Oral Fluid Drug Testing with Oral-Eze BENEFITS AND PRICING Q: What benefits does Oral-Eze present? A: The Oral-Eze Oral Fluid Collector has a built-in indicator for determining

More information

Pennsylvania Hospital & Surgery Center ADMINISTRATIVE POLICY MANUAL

Pennsylvania Hospital & Surgery Center ADMINISTRATIVE POLICY MANUAL Page 1 Issued: May 2003 Committee Approval: Human Resources Administrative Policy Review Committee: May 2004 May 2005 May 2007 June 2008 Attachment(s): Consent Acknowledgement Form Related Policies: POLICY

More information

Collection Instructions for ARUP Drug Screen Kit #49204

Collection Instructions for ARUP Drug Screen Kit #49204 Collection Instructions for ARUP Drug Screen Kit #49204 Manufacturer Purpose of Kit / Reagent (tests) Kit / Reagent Contents (list components) Other Supplies Needed ARUP Laboratories For Point of Collection

More information

Pharmacotherapy Update

Pharmacotherapy Update Summer 2013 Special points of interest: New Drug in Pipeline: review of a novel antidiabetic medication currently in development Drug Information Corner: Use of Vitamin D for treating statin induced myalgias

More information

PtProtect Pain Medication Management Program Monitors Patient Compliance

PtProtect Pain Medication Management Program Monitors Patient Compliance PHYSICIAN UPDATE 2013 Edition PtProtect Pain Medication Management Program Monitors Patient Compliance The PtProtect (Patient Protect) program offers pain medication management panels designed to improve

More information

PAYMENT POLICY STATEMENT

PAYMENT POLICY STATEMENT PAYMENT POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 01/01/2014 04/05/2017 04/05/2016 Policy Name Policy Number Drug Screening Tests PY-0020 Policy Type

More information

Clinical Drug Testing in Primary Care

Clinical Drug Testing in Primary Care Clinical Drug Testing in Primary Care Technical Assistance Publication Series TAP 32 Clinical Drug Testing in Primary Care TAP Technical Assistance Publication Series 32 U.S. DEPARTMENT OF HEALTH AND

More information

The Role of Urine Drug Testing In Chronic Pain Management: 2013 Update

The Role of Urine Drug Testing In Chronic Pain Management: 2013 Update PRINTER-FRIENDLY VERSION AVAILABLE AT PAINMEDICINENEWS.COM The Role of Urine Drug Testing In Chronic Pain Management: 2013 Update LYNN R. WEBSTER, MD President, American Academy of Pain Medicine Medical

More information

1.7.8.5 EFFECTIVE DATE: February 12, 2010, unless a later date is cited at the end of a section. [1.7.8.5 NMAC - Rp, 1.7.8.5 NMAC, 02/12/2010]

1.7.8.5 EFFECTIVE DATE: February 12, 2010, unless a later date is cited at the end of a section. [1.7.8.5 NMAC - Rp, 1.7.8.5 NMAC, 02/12/2010] TITLE 1 CHAPTER 7 PART 8 GENERAL GOVERNMENT ADMINISTRATION STATE PERSONNEL ADMINISTRATION DRUG AND ALCOHOL ABUSE 1.7.8.1 ISSUING AGENCY: State Personnel Board. [1.7.8.1 NMAC - Rp, 1.7.8.1 NMAC, 02/12/2010]

More information

The CPT code for Human papillomavirus (HPV) has changed from 87621 to 87624. This code (87624) covers testing for HPV High Risk genotypes.

The CPT code for Human papillomavirus (HPV) has changed from 87621 to 87624. This code (87624) covers testing for HPV High Risk genotypes. January 2015 2015 CPT Code Updates Dear Client: The American Medical Association (AMA) publishes the Current Procedural Terminology (CPT) Coding Manual on an annual basis. For 2015, the AMA made several

More information

Toxicology/DAU Testing by Mass Spectrometry

Toxicology/DAU Testing by Mass Spectrometry Toxicology/DAU Testing by Mass Spectrometry AACC Conference: Mass Spectrometry in the Clinical Lab September 17, 2013 Kara Lynch, PhD, DABCC University of California San Francisco Disclosures Research

More information

REACH AIR MEDICAL SERVICES SUBSTANCE ABUSE POLICY FOR APPLICANTS APPLYING FOR SAFETY-SENSITIVE POSITIONS

REACH AIR MEDICAL SERVICES SUBSTANCE ABUSE POLICY FOR APPLICANTS APPLYING FOR SAFETY-SENSITIVE POSITIONS EFFECTIVE DATE: 06/01/2013 REACH AIR MEDICAL SERVICES SUBSTANCE ABUSE POLICY FOR APPLICANTS APPLYING FOR SAFETY-SENSITIVE POSITIONS (FOR TESTING TO BE CONDUCTED IN CALIFORNIA [excluding the City of San

More information

Substance Abuse Prevention Program

Substance Abuse Prevention Program Planning, Design and Construction 14528 S Outer Forty Suite 100 Chesterfield, MO 63017 (314) 628-3494 (314) 628-3715 Substance Abuse Prevention Program REFERENCES: In an effort to create a safe workplace,

More information

FREQUENTLY ASKED QUESTIONS Hair Testing

FREQUENTLY ASKED QUESTIONS Hair Testing MRCH 2011 FREUENTLY SKED UESTIONS Hair Testing DRUGS & CUTOFFS TECHNICL EXPLNTIONS What testing methodology is used for hair tests? two-tiered testing process is used: 1) portion of the hair sample is

More information

Urine Drug Toxicology and Pain Management Testing. Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA

Urine Drug Toxicology and Pain Management Testing. Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Urine Drug Toxicology and Pain Management Testing Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Learning Objectives Describe what chronic pain is, who is affected and

More information

Frequently Asked Questions About Syva s EMIT Drug-Abuse Tests. Test Result Interpretation. Answers for life.

Frequently Asked Questions About Syva s EMIT Drug-Abuse Tests. Test Result Interpretation. Answers for life. Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring

More information

DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015

DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015 DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015 The signatory parties recognize that drug abuse is an illness that creates serious problems for workers, their families, the workplace and

More information

CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES

CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES Vina SPIEHLER 1, Dene BALDWIN 2, Christopher HAND 2 1 DABFT, Newport Beach, United States of America 2 Cozart

More information

Why do employers drug test? How is drug testing conducted and how accurate is it?

Why do employers drug test? How is drug testing conducted and how accurate is it? Workplace Drug Testing Drug testing is one action an employer can take to determine if employees or job applicants are using drugs. It can identify evidence of recent use of alcohol, prescription drugs

More information

NALCOR ENERGY ALCOHOL AND DRUG PROGRAM REQUIREMENTS FOR CONTRACTORS

NALCOR ENERGY ALCOHOL AND DRUG PROGRAM REQUIREMENTS FOR CONTRACTORS NALCOR ENERGY ALCOHOL AND DRUG PROGRAM REQUIREMENTS FOR CONTRACTORS At Nalcor Energy, safety is our top priority. We take collective pride in our commitment to ensuring employees, contractors and visitors

More information

Pain Medication Management Program Monitors Patient Compliance

Pain Medication Management Program Monitors Patient Compliance PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your

More information

Diagnostic Accuracy Study Protocol. Pain Physician 2010; 13:E1-E22 ISSN 2150-1149. www.painphysicianjournal.com

Diagnostic Accuracy Study Protocol. Pain Physician 2010; 13:E1-E22 ISSN 2150-1149. www.painphysicianjournal.com Pain Physician 2010; 13:E1-E22 ISSN 2150-1149 Diagnostic Accuracy Study Protocol Protocol for Accuracy of Point of Care (POC) or In-Office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective

More information

Technical Note. Introduction. Edward J. Cone. Lance Presley, Michael Lehrer, William Seiter, and Melissa Smith

Technical Note. Introduction. Edward J. Cone. Lance Presley, Michael Lehrer, William Seiter, and Melissa Smith Technical Note Oral Fluid Testing for Drugs of Abuse: Positive Prevalence Rates by Intercept Immunoassay Screening and GC MS MS Confirmation and Suggested Cutoff Concentrations * Edward J. Cone ConeChem

More information

OU MEDICAL CENTER Human Resource Policy and Procedure Manual. Subject: Drug and Alcohol

OU MEDICAL CENTER Human Resource Policy and Procedure Manual. Subject: Drug and Alcohol OU MEDICAL CENTER Human Resource Policy and Procedure Manual Subject: Drug and Alcohol Section: HR 6-10 Page: 1 of 5 Origination Date: 6/2004 Revision Date: 2/2006, 9/2008, 7/2009 Coverage: All OUMC employees

More information

Tests Impacted by 2015 CPT Changes

Tests Impacted by 2015 CPT Changes Toxicology Changes for 2015 HPV Examples of Toxicology Panels Molecular Pathology, FISH and Anatomic Pathology 1 Toxicology Changes for 2015 80100 Test Code Dos Test Name 2015 2015 Medicare 5229 Drug Screen,

More information

MOSAIC DES MOINES Alcohol/Drug Free Workplace Policy

MOSAIC DES MOINES Alcohol/Drug Free Workplace Policy MOSAIC DES MOINES Alcohol/Drug Free Workplace Policy Purpose: To help safeguard employee health, provide a safe and productive workplace, and supply our people served with high quality service, Mosaic

More information

Drug Testing & Office Based Detoxification

Drug Testing & Office Based Detoxification Drug Testing & Office Based Detoxification Laxmaiah Manchikanti, M.D. 1 DISCLAIMER Chief Executive Officer, ASIPP, SIPMS Medical Director, PMCP, ASC, PCS Associate Clinical Professor Anesthesiology and

More information

HEAT AND FROST INSULATORS AND ALLIED WORKERS LOCAL 45 JOINT APPRENTICESHIP AND TRAINING COMMITTEE DRUG-FREE SUBSTANCE ABUSE POLICY AND PROCEDURE

HEAT AND FROST INSULATORS AND ALLIED WORKERS LOCAL 45 JOINT APPRENTICESHIP AND TRAINING COMMITTEE DRUG-FREE SUBSTANCE ABUSE POLICY AND PROCEDURE HEAT AND FROST INSULATORS AND ALLIED WORKERS LOCAL 45 JOINT APPRENTICESHIP AND TRAINING COMMITTEE I. PURPOSE DRUG-FREE SUBSTANCE ABUSE POLICY AND PROCEDURE The purpose of this Substance Abuse Policy (hereinafter

More information

CERTIFICATE OF COMPLIANCE OF

CERTIFICATE OF COMPLIANCE OF CERTIFICATE OF COMPLIANCE OF Name of Contractor Company GOLDEN TRIANGLE CONTRACTOR SUBSTANCE AND ALCOHOL ABUSE PROGRAM November 2002 Edition Adopted and implemented by [Name of Contractor Company] ( Company

More information

The DRE DUI & DRUGS. Captain George Crum Fullerton Police Department

The DRE DUI & DRUGS. Captain George Crum Fullerton Police Department The DRE DUI & DRUGS Captain George Crum Fullerton Police Department What is a DRE? Drug Recognition Expert Experienced officer Selected by their department Special training in detecting drug influence/impairment

More information

Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment

Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment Clinical Position Statement Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment CLINICAL POSITION STATEMENT In most cases, immunoassay (qualitative) drug testing is sufficient for

More information

2013 Annual Toxicology Report

2013 Annual Toxicology Report 213 Annual Toxicology Report Department of Justice Forensic Science Division Toxicology Department 2679 Palmer Street Missoula, MT 5988 DOJTOX@mt.gov Personnel Phil Kinsey Scott Larson Scott Schlueter

More information

Drug Testing for Criminal Justice Involved Individuals in Michigan

Drug Testing for Criminal Justice Involved Individuals in Michigan Drug Testing for Criminal Justice Involved Individuals in Michigan Oakland County Drug Court Professionals Barbara M. Hankey, Manager Oakland County Community Corrections Session Goals O To present the

More information

June 2016 Updated Crosswalk:

June 2016 Updated Crosswalk: June 2016 Updated Crosswalk: 2016 HCPCS G0279 G6001 G6002 G6003 G6004 deleted f Radiology Coding BCBSNC currently considers this service investigational and will not cover either the HCPCS CPT s. Diagnostic

More information

Urine Drug Testing in Pain Medicine

Urine Drug Testing in Pain Medicine 260 Journal of Pain and Symptom Management Vol. 27 No. 3 March 2004 Review Article Urine Drug Testing in Pain Medicine Howard A. Heit, MD, FACP, FASAM and Douglas L. Gourlay, MD, MSc, FRCPC, FASAM Department

More information

Ways to Deceive Drug Testing

Ways to Deceive Drug Testing Opioid Risk Management June 26-27, 2008 Ways to Deceive Drug Testing Theodore F. Shults, JD, MS Chairman American Association of Medical Review Officers Durham, NC 1 The Smoking Thoroughbred 2 1. Eliminate

More information

HELPING YOUR BUSINESS DO MORE Webinar Series

HELPING YOUR BUSINESS DO MORE Webinar Series HELPING YOUR BUSINESS DO MORE Webinar Series The Employers Council of Iowa, the Greater Des Moines Partnership, Kaplan University and Iowa Works bring you a series of educational webinars. These webinars

More information

BEST PRACTICES IN DRUG TESTING OF HEALTHCARE PROFESSIONALS

BEST PRACTICES IN DRUG TESTING OF HEALTHCARE PROFESSIONALS ENSURING COMPLIANCE: EXPLORING BEST PRACTICES IN DRUG TESTING OF HEALTHCARE PROFESSIONALS Martha E. Brown, MD Associate Medical Director, PRN and UF Associate Professor Addiction Medicine Division Disclosures

More information

I.M.P.A.C.T. National Drug Testing and Substance Abuse Program and Guidelines

I.M.P.A.C.T. National Drug Testing and Substance Abuse Program and Guidelines IRONWORKER MANAGEMENT PROGRESSIVE ACTION COOPERATIVE TRUST I.M.P.A.C.T. National Drug Testing and Substance Abuse Program and Guidelines Effective The processes and procedures outlined may be used as a

More information

Clinical Drug Screening and/or Drug Testing

Clinical Drug Screening and/or Drug Testing Manual: Policy Title: Reimbursement Policy Clinical Drug Screening and/or Drug Testing Section: Laboratory & Pathology Subsection: None Date of Origin: 10/26/2011 Policy Number: RPM016 Last Updated: 1/8/2016

More information

Practical Aspects of Drug Testing in Human Hair

Practical Aspects of Drug Testing in Human Hair Practical Aspects of Drug Testing in Human Hair Laboratory Perspective James A. Bourland, Ph.D., DABFT FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION Overview of Collection Process FOR INTERNAL USE

More information

I.M.P.A.C.T. Revised. SUBSTANCE ABUSE TESTING POLICY Part I. PROCEDURE MANUAL Part II

I.M.P.A.C.T. Revised. SUBSTANCE ABUSE TESTING POLICY Part I. PROCEDURE MANUAL Part II I.M.P.A.C.T. Revised SUBSTANCE ABUSE TESTING POLICY Part I & PROCEDURE MANUAL Part II REVISED June 2011 Revised Substance Abuse Policy Part I Table of Contents I. Preface I. Statement of Policy.........

More information

LC-MS for Pain Management Support. Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories

LC-MS for Pain Management Support. Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline Overview of drug testing, as a component of the therapeutic plan, in the management of chronic

More information

LC-MS for Pain Management Support

LC-MS for Pain Management Support LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline Overview of drug testing, as a component of the therapeutic plan, in the management of chronic

More information

Drug Testing to Support Pain Management

Drug Testing to Support Pain Management NATIONAL REFERENCE LABORATORY Drug Testing to Support Pain Management 500 Chipeta Way, Salt Lake City, UT 84108 (800) 522-2787 (801) 583-2787 www.aruplab.com www.arupconsult.com ARUP is an enterprise of

More information

Rationale for Urine Drug Testing (UDT)

Rationale for Urine Drug Testing (UDT) Rationale for Urine Drug Testing (UDT) Help to identify drug misuse/addiction Prior to starting opioid treatment Assist in assessing adherence during opioid therapy As requirement of therapy w/ an opioid

More information

Drugs of Abuse Testing

Drugs of Abuse Testing Drug Testing is the Substance Abuse Testing division of ACL Laboratories. Whether your drug testing needs are to comply with Federally mandated employee drug screening rules, to provide a drug free workplace

More information

What Americans Believe. Grant Beardsley, MS, MT(ASCP) 10/12/2015. Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse

What Americans Believe. Grant Beardsley, MS, MT(ASCP) 10/12/2015. Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse Grant D. Beardsley, M.S., MT(ASCP) Clinical Toxicologist, Grant Beardsley, MS, MT(ASCP) I have nothing to disclose. I

More information

Drugs of Abuse. Dr Charles Appleton - MBBS, FRCPA Director of Biochemistry/Toxicology. Occupational Pathology Services

Drugs of Abuse. Dr Charles Appleton - MBBS, FRCPA Director of Biochemistry/Toxicology. Occupational Pathology Services Drugs of Abuse Dr Charles Appleton - MBBS, FRCPA Director of Biochemistry/Toxicology Occupational Pathology Services CONTENTS Why implement a drug testing program 2 Why not impairment testing 2 Choice

More information

Amphetamines Assay 2 SUMMARY 3 METHODOLOGY 4 REAGENTS 1 INTENDED USE

Amphetamines Assay 2 SUMMARY 3 METHODOLOGY 4 REAGENTS 1 INTENDED USE 2 SUMMARY August 2010 Catalog Quantity/ Number Product Description Volume OSR9C229 Emit II Plus Amphetamines Assay OSR9C618 R1 (Antibody/Substrate Reagent 1) OSR9C648 R2 (Enzyme Reagent 2) 2 x 33 ml 2

More information

Opiates Agreements and Drug testing in Pain Management

Opiates Agreements and Drug testing in Pain Management Opiates Agreements and Drug testing in Pain Management Lokesh Ningegowda, MD Department of Pain Management Anesthesiology Institute, Cleveland Clinic Director Department of Pain Management at Twinsburg

More information

Implementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center

Implementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center Clinical Chemistry / POC Testing f o r Dr u g s o f Ab u s e in t h e ED Implementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center

More information

3.1. The procedure shall be applicable to all University employees.

3.1. The procedure shall be applicable to all University employees. LINCOLN UNIVERSITY Procedure: Confirmatory Testing for Substance Abuse Procedure Number: HRM 113p Effective Date: October 2008 Revisions: Review Officer: Chief Human Resources Officer 1. Purpose 1.1. It

More information

Drug- and Alcohol-Related Intoxication Deaths in Maryland, 2014

Drug- and Alcohol-Related Intoxication Deaths in Maryland, 2014 Maryland Department of Health and Mental Hygiene Larry Hogan, Governor Boyd Rutherford, Lt. Governor Van Mitchell, Secretary May, 215 Drug- and Alcohol-Related Intoxication Deaths in Maryland, 214 Table

More information

Bermuda Hospitals Board Drug Screening Programme

Bermuda Hospitals Board Drug Screening Programme Bermuda Hospitals Board Drug Screening Programme Tiana Outerbridge, Employee Health Services Manager Dr. Cathryn Siddle, Employee Health Services Physician Angela Fraser-Pitcher, Human Resources Director

More information

(Updated: 10/12/2015)

(Updated: 10/12/2015) DRUG TESTING & BACKGROUND CHECK Pfizer s Drug Testing and Background Check Requirements for Contingent Workers and Suppliers, Including Criminal and MVR Record Checks, FDA Debarment Database and DEA Controlled

More information

C. The prospective employee must thoroughly read the LFCC Pre-Employment Drug

C. The prospective employee must thoroughly read the LFCC Pre-Employment Drug Pre-Employment Drug Screening Policy Policy No. 40001 Effective Date March 2006 Revision Date Revision No. Approved: John J. Ski Sygielski and President s Cabinet Date: March 2006 1.0 Purpose Substance

More information

Simultaneous Quantitation of 43 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method

Simultaneous Quantitation of 43 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method Simultaneous Quantitation of 4 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method Xiang He and Marta Kozak, Thermo Fisher Scientific, San Jose, CA Application Note 76 Key Words TSQ Quantum Access

More information

Clinic Reference Guide

Clinic Reference Guide Clinic Reference Guide 2010 Alliance Toxicology LLC PO Box 5000, PMB 190 Rancho Santa Fe, CA 92067 AllianceToxicologyLLCprovidesclinicaldrugtestingservicesforphysicians.Our companyprovidesacomprehensivedrugtestingpanelwhichincludesover40

More information

Update on Drug Impaired Driving. WTSC Impaired Driver Conference SeaTac, December 2006

Update on Drug Impaired Driving. WTSC Impaired Driver Conference SeaTac, December 2006 Update on Drug Impaired Driving WTSC Impaired Driver Conference SeaTac, December 2006 12/4/2007 Alcohol, Drugs and Driving Household Survey, 2004 (prior year) Any Illicit Drug Use 19.9 Million 8.3% Marijuana

More information

Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications

Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications Introduction The resolving power of chromatography combined with the sensitivity and selectivity

More information

Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications

Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications TECHNICAL NOTE Toxicology Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications Introduction The resolving power of chromatography combined with

More information

Number: TBD EFFECTIVE DATE: JULY 31, 2000 PROCEDURE STATEMENT

Number: TBD EFFECTIVE DATE: JULY 31, 2000 PROCEDURE STATEMENT Number: TBD EFFECTIVE DATE: JULY 31, 2000 PROCEDURE STATEMENT Policy Area: Supervision Issue: Drug Surveillance Action/Guidance: Chain-of-Custody Procedures Context: CSOSA conducts drug testing on all

More information

Department of Health and Human Services. No. 94 May 15, 2015. Part II

Department of Health and Human Services. No. 94 May 15, 2015. Part II Vol. 80 Friday, No. 94 May 15, 2015 Part II Department of Health and Human Services Substance Abuse and Mental Health Services Administration Mandatory Guidelines for Federal Workplace Drug Testing Programs;

More information

DRI Amphetamines Assay

DRI Amphetamines Assay s Assay For In Vitro Diagnostic Use 10014585 (3 x 18 ml) 0017 (100 ml Kit) 0018 (500 ml Kit) Intended Use The s assay is intended for the qualitative or semi-quantitative determination of amphetamine and

More information

A Report on Marijuana and Prescription Drugs

A Report on Marijuana and Prescription Drugs Prescription Drug Misuse in America A Report on Marijuana and Prescription Drugs Table of Contents Summary 2 Prescription Drug Misuse is Prevalent 6 Marijuana: The Most Misused Drug 8 Recreational Marijuana

More information

15.110 ALCOHOL AND DRUG TESTING OF DEPARTMENT PERSONNEL

15.110 ALCOHOL AND DRUG TESTING OF DEPARTMENT PERSONNEL 15.110 ALCOHOL AND DRUG TESTING OF DEPARTMENT PERSONNEL Reference: Administrative Regulation #52 (06/07) Manual of Rules and Regulations: 1.01, 1.02, 2.26 A/B, 6.01, 6.02 A/B, 6.03, 6.04, 6.05, 11.03 Public

More information

Urine Drug Testing. Clinical Practice

Urine Drug Testing. Clinical Practice Urine Drug Testing in Clinical Practice The Art and Science of Patient Care EDITION 5 Target Audience: Physicians who treat patients with chronic pain There are no prerequisites Release date: June 15,

More information

Urine Drug Testing in Clinical Practice

Urine Drug Testing in Clinical Practice Urine Drug Testing in Clinical Practice DISPELLING THE MYTHS & DESIGNING STRATEGIES Edition 3, 2006 Target Audience: Healthcare professionals who treat patients with pain. Sponsored by the California Academy

More information

Hair Drug & Alcohol Testing FAQs

Hair Drug & Alcohol Testing FAQs HAIR DRUG TESTING More than DNA Hair Drug & Alcohol Testing FAQs Need advice about testing? Contact us using our online SMS service or call Cellmark free on 0800 043 4247 2045 Introduction Cellmark is

More information

Employer Drug Testing Solutions

Employer Drug Testing Solutions Employer Drug Testing Solutions A broad range of testing and collection options backed by a service-oriented culture that s committed to showing we re there when you need us. Choose drug testing to help

More information

South Carolina Drug Statutes South Carolina Code of Laws: Title 44 Health Code

South Carolina Drug Statutes South Carolina Code of Laws: Title 44 Health Code SCHEDULE CRITERIA AND COMPOSITION SCHEDULE I: (a) A high potential for abuse; (b) No accepted medical use in treatment in the United States; (c) A lack of accepted safety for use in treatment under medical

More information

A Best Practices Review of Drug Detection for Court Professionals. By: Paul L. Cary Toxicology Laboratory University of Missouri

A Best Practices Review of Drug Detection for Court Professionals. By: Paul L. Cary Toxicology Laboratory University of Missouri A Best Practices Review of Drug Detection for Court Professionals By: Paul L. Cary Toxicology Laboratory University of Missouri Best Practices frequency of testing random testing witness collection & specimen

More information

URINE DRUG TESTS IN A PRIVATE CHRONIC PAIN PRACTICE

URINE DRUG TESTS IN A PRIVATE CHRONIC PAIN PRACTICE URINE DRUG TESTS IN A PRIVATE CHRONIC PAIN PRACTICE The likelihood of surprises leads to the recommendation that virtually all patients who receive chronic opioids should be tested initially, occasionally

More information

Employee Substance Abuse

Employee Substance Abuse Guideline # 150.05 Township Of Jackson, Fire District 3, Station 55 Standard Operating Guidelines Employee Substance Abuse Date: 6/09 N EDUCATION: The Board shall implement and use an education program,

More information

PERSPECTIVES ON WORKPLACE DRUG TESTING IN SOUTH AFRICA

PERSPECTIVES ON WORKPLACE DRUG TESTING IN SOUTH AFRICA PERSPECTIVES ON WORKPLACE DRUG TESTING IN SOUTH AFRICA Dr Tim Laurens [PhD, FRSC, MFSS] Forensic Division, Dept of Chemistry E-mail: tim.laurens@up.ac.za Tel: +27 82 891 4886 / +27 12 420 2515 Website:

More information

Urine Drug Testing In Chronic Pain

Urine Drug Testing In Chronic Pain Pain Physician 2011; 14:123-143 ISSN 1533-3159 Comprehensive Review Urine Drug Testing In Chronic Pain Paul J. Christo, MD 1, Laxmaiah Manchikanti, MD 2, Xiulu Ruan, MD 3, Michael Bottros, MD 1, Hans Hansen,

More information